Trial Profile

Inter-lot Consistency Clinical Trial of Adsorbed Cell-free DTP (Three-component) Combined Vaccine

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 Feb 2026 According to CanSinoBIO media release, company announced that the Center for Drug Evaluation, National Medical Products Administration of the Peoples Republic of China (NMPA) has granted priority review status to the Companys new drug application (NDA) for its absorbed diphtheria, tetanus, and acellular pertussis (components) combined vaccine (the DTcP) for infants (below 2 years old) (the DTcP Infant).
15 Aug 2025 Status changed from recruiting to active, no longer recruiting.
30 Mar 2025 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com